Attached files

file filename
EX-31.2 - EX-31.2 - Relay Therapeutics, Inc.d24902dex312.htm
EX-31.1 - EX-31.1 - Relay Therapeutics, Inc.d24902dex311.htm
EX-10.7 - EX-10.7 - Relay Therapeutics, Inc.d24902dex107.htm
10-Q - 10-Q - Relay Therapeutics, Inc.d24902d10q.htm

Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Relay Therapeutics, Inc. (the “Company”) for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:

 

  (1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 12, 2020

    By:   /S/    SANJIV K. PATEL        
     

Sanjiv K. Patel

     

President and Chief Executive Officer

(Principal Executive Officer)

 

Date: November 12, 2020

    By:   /S/    THOMAS CATINAZZO        
     

Thomas Catinazzo

     

Senior Vice President, Finance

(Principal Accounting Officer and Principal Financial Officer)